Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F R Robertson

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Breast (Edinburgh, Scotland)|November 22, 2016
Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situJ Mathew, R Karia, D A L Morgan, et al.
British Journal of Cancer|July 17, 2003
Prognostic factors for patients with hepatic metastases from breast cancerL Wyld, E Gutteridge, S E Pinder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatmentA Howell, J F R Robertson, J Quaresma Albano, et al.
The Journal of Pathology|November 5, 2003
Expression of p27kip1 in breast cancer and its prognostic significanceA Barnes, S E Pinder, J A Bell, et al.
The Journal of Pathology|October 1, 2008
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survivalJ M W Gee, J J Eloranta, J C Ibbitt, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2005
Endocrine treatment options for advanced breast cancer--the role of fulvestrantJ F R Robertson, S E Come, S E Jones, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2010
Technical validation of an autoantibody test for lung cancerA Murray, C J Chapman, G Healey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 10, 2012
The sequential use of endocrine treatment for advanced breast cancer: where are we?C Barrios, J F Forbes, W Jonat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-upS J Johnston, F S Kenny, B M Syed, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancerJ F R Robertson, G G Steger, P Neven, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Breast (Edinburgh, Scotland)|November 22, 2016
Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situJ Mathew, R Karia, D A L Morgan, et al.
British Journal of Cancer|July 17, 2003
Prognostic factors for patients with hepatic metastases from breast cancerL Wyld, E Gutteridge, S E Pinder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatmentA Howell, J F R Robertson, J Quaresma Albano, et al.
The Journal of Pathology|November 5, 2003
Expression of p27kip1 in breast cancer and its prognostic significanceA Barnes, S E Pinder, J A Bell, et al.
The Journal of Pathology|October 1, 2008
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survivalJ M W Gee, J J Eloranta, J C Ibbitt, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2005
Endocrine treatment options for advanced breast cancer--the role of fulvestrantJ F R Robertson, S E Come, S E Jones, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2010
Technical validation of an autoantibody test for lung cancerA Murray, C J Chapman, G Healey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 10, 2012
The sequential use of endocrine treatment for advanced breast cancer: where are we?C Barrios, J F Forbes, W Jonat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-upS J Johnston, F S Kenny, B M Syed, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancerJ F R Robertson, G G Steger, P Neven, et al.
Pageof 5